Login / Signup

Design of Coibamide A Mimetics with Improved Cellular Bioactivity.

Takashi KitamuraRikito SuzukiShinsuke InukiHiroaki OhnoKerry L McPhailShinya Oishi
Published in: ACS medicinal chemistry letters (2021)
Coibamide A, a cyclic depsipeptide isolated from a Panamanian marine cyanobacterium, shows potent cytotoxic activity via the inhibition of the Sec61 translocon. We designed a coibamide A mimetic in which the ester linkage between MeThr and d-MeAla in coibamide A was replaced with an alkyl linker to provide a stable macrocyclic scaffold possessing a MeLys(Me) residue. Taking advantage of a facile solid-phase synthetic approach, an structure-activity relationship (SAR) study of the newly designed macrocyclic structure was performed, with a focus on altering the pattern of N -methyl substitution and amino acid configurations. Overall, the simplified macrocyclic scaffold with an alkyl linker resulted in a significantly reduced cytotoxicity. Instead, more potent coibamide A derivatives with a β-(4-biphenylyl)alanine (Bph) group were identified after the optimization of the Tyr(Me) position in the original macrocyclic scaffold of coibamide A based on the characteristic apratoxin A substructures. The similar SAR between coibamide A and apratoxin A suggests that the binding site of the Tyr(Me) side chain at the luminal end of Sec61α may be shared.
Keyphrases
  • structure activity relationship
  • amino acid
  • tissue engineering
  • genome wide
  • gene expression
  • anti inflammatory
  • quantum dots
  • gold nanoparticles
  • highly efficient